Latest Sulfoxides Stories
FRAZER, Pa., Jan. 25, 2011 /PRNewswire/ -- Cephalon, Inc.
RADNOR, Pa., Jan. 19, 2011 /PRNewswire/ -- HTH Worldwide, a global health and safety services company, today announced the expansion of its mobile and online brand name medication translation guide for world travelers.
FRAZER, Pa., Dec. 27, 2010 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the company received a second Complete Response Letter from the U.S.
Despite the reassurances of Pasternak and Hviid in their study, "Use of Proton-Pump Inhibitors (PPI) in Early Pregnancy and the Risk of Birth Defects," featured in the Nov. 24 issue of the New England Journal of Medicine, an epidemiologist from Boston University School of Medicine (BUSM) believes that further studies are needed.
FRAZER, Pa., Oct. 22 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that Risk Evaluation and Mitigation Strategies (REMS) for its medications NUVIGILÂ® (armodafinil) Tablets [C-IV] and PROVIGILÂ® (modafinil) Tablets [C-IV] have been approved by the U.S.
The impact of upper GI conditions, like gastroesophageal reflux disease (GERD) and functional dyspepsia, on sleepâ€”and treatments aimed at providing relief to heartburn/acid reflux patients who suffer from disordered sleepâ€”were explored in three new studies related to sleep dysfunction presented today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.
DEXILANT is the First Proton Pump Inhibitor (PPI) with a DUAL DELAYED RELEASE (DDR) Technology MISSISSAUGA, ON, Sept.
PARIS, July 27 /PRNewswire-FirstCall/ -- Medco Research Institute(TM), LLC, a wholly owned subsidiary of Medco Health Solutions, Inc.
WOODCLIFF LAKE, N.J., July 1 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 20mg/1100mg and 40mg/1100mg strengths of omeprazole and sodium bicarbonate capsules to the trade.
- A volcanic mudflow.